
Eledon Pharmaceuticals rose 31.9% from $1.44 to $1.90, ahead of the S&P 500's +4.7%. Its worst day was Nov 12 (−11.4%), and its low came Nov 21 at $1.44.
Nov 21, 2025 – Nov 19, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Eledon Pharmaceuticals shares rose 11.8%, while the S&P 500 rose 1.5%.
+11.8% · S&P 500 +1.5%
Eledon Pharmaceuticals shares rose 11.2%, while the S&P 500 rose 1.9%.
+11.2% · S&P 500 +1.9%
Story events cover the past 12 months · Times ET
EPS of $-0.10 beat the $-0.20 estimate on $0.00 revenue.
+1.1% · S&P 500 −1.4%
Eledon Pharmaceuticals shares rose 13.7%, while the S&P 500 rose 2.9%.
+13.7% · S&P 500 +2.9%
Eledon Pharmaceuticals shares rose 13.0%, while the S&P 500 rose 0.2%.
+13.0% · S&P 500 +0.2%
EPS of $-0.33 missed the $-0.23 estimate on $0.00 revenue.
+1.8% · S&P 500 +0.8%
Eledon Pharmaceuticals closed at its highest level of the year, 192.4% above where the year started.
+7.1% · S&P 500 −0.3%
EPS of $-0.27 missed the $-0.16 estimate on $0.00 revenue.
−4.3% · S&P 500 −0.2%
Eledon Pharmaceuticals shares rose 14.5%, while the S&P 500 rose 0.3%.
+14.5%, the year's best day · S&P 500 +0.3%
EPS of $-0.16 beat the $-0.19 estimate on $0.00 revenue.
−10.6% · S&P 500 −0.4%
Where it ended: a close of $1.90 on Nov 19, 2026. Up next: Q4 2026 earnings on Mar 18, 2027 (EPS est. $-0.18).
Nothing in the past 12 months.
All ELDN dividend historyReplay the year: the line draws itself and stops at each of the 10 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for ELDN and SPY from Benzinga historical bars. Not investment advice.